Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2025)

Dr. William Makis, a radiologist and cancer researcher, has developed a "hybrid orthomolecular" protocol that incorporates ivermectin as a repurposed drug for cancer treatment. This approach targets cancer stem cells and mitochondrial dysfunction, often in combination with other therapies like benzimidazoles (e.g., mebendazole or fenbendazole), vitamins, and dietary changes.

The protocol is based on preclinical studies, case reports, and his clinical observations, but it remains experimental and unapproved by regulatory bodies like the FDA for cancer use.

Dosages are weight-based (e.g., for a 70 kg/154 lb person, 1 mg/kg = 70 mg) and stratified by cancer severity: low-grade (early-stage or slow-growing), intermediate-grade (moderately progressive), or high-grade (aggressive, metastatic, or "turbo" cancers). Always consult a healthcare provider for personalization, monitoring (e.g., liver/kidney function), and integration with conventional treatments.

Dr. William Makis's Recommended Ivermectin Dosages for Cancer
Key Ivermectin Dosage GuidelinesIvermectin is typically taken orally with a fatty meal for better absorption. The protocol suggests cycles of 6 days on/1 day off, or 3 weeks on/1 week off, over 3–12 months, with long-term maintenance possible at lower doses. Higher doses are reported as safe in his observations, but monitor for side effects like gastrointestinal issues or transient visual disturbances.
  • Low-grade (e.g., early-stage, remission maintenance, or prophylaxis): Dosage of 0.5 mg/kg, taken 3 times per week (e.g., Mon/Wed/Fri). Suitable for prevention or stable cases; complements other protocol elements.
  • Intermediate-grade (e.g., moderately progressive or challenging cases): Dosage of 0.5–1 mg/kg, taken 3 times per week, or daily if needed. Escalate based on response; often combined with benzimidazoles for synergy.
  • High-grade (e.g., aggressive, metastatic, or turbo cancers): Dosage of 1–2 mg/kg (up to 2.5 mg/kg in severe cases), taken daily. For advanced disease; case reports show remissions in 2–6 months when used adjunctively.
Example Case Outcomes from Makis's Reports
  • Stage 3 ovarian cancer: 12 mg daily (approx. 0.2 mg/kg for a 60 kg person) with chemotherapy led to complete resolution in 2 months.
  • Stage 3 follicular lymphoma (83-year-old): 1 mg/kg daily achieved near-total remission in 6 months.
  • Recurrent prostate cancer (54-year-old): 1.5 mg/kg daily resulted in remission in 4 months.
Broader Protocol ContextMakis's full protocol includes 7 components for synergy, but ivermectin is a core element. Other key parts (Hybrid orthomolecular protocol 2024):
  • Benzimidazoles (e.g., mebendazole): 200–1,500 mg/day depending on grade, or fenbendazole 222–1,000 mg 3–6x/week.
  • Vitamin D3: 2,000–50,000 IU/day to reach 80 ng/mL blood levels.
  • IV Vitamin C: 1.5 g/kg, 2–3x/week for intermediate/high-grade.
  • Ketogenic diet: Restrict carbs to induce ketosis (glucose-ketone index ≤2.0).
  • Precautions: Source from reputable pharmacies; avoid if pregnant or with certain contraindications. Evidence is anecdotal and preclinical—large trials are lacking.
This information is for educational purposes only and not medical advice. For his clinic or substack details, search directly on those platforms.

Comments

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2025 Edition)

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2025)

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2025)

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 300 Patients (2025)

Fenbendazole and the Joe Tippens Cancer Protocol: A Comprehensive Guide (2025)

Fenbendazole Dosage for Cancer in Humans: Benefits, Risks, and Guidelines (2025)

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

How One Cancer Survivor Triggered Interest in Repurposed Anti-Parasitic Drugs

2025 Study: Ivermectin and Balstilimab for Stage 4 Triple Negative Breast Cancer - Cedars-Sinai Medical Center Study